ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2522

Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study

Sumanth Chandrupatla1, Kranti Rumalla2 and Jasvinder Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2Northwestern School of Medicine, Chicago, IL

Meeting: ACR Convergence 2023

Keywords: Administrative Data, Arthroplasty, Outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Primary total hip arthroplasty (THA) patients often have concomitant medical comorbidities. This study aims to identify the impact of diabetes mellitus (DM) on inpatient clinical and healthcare utilization outcomes in patients, and whether this association varies by the underlying primary diagnoses.

Methods: We identified patients over the age of 18 who underwent THA in the 2019 National Inpatient Sample (NIS). We stratified patients by primary diagnosis into hip osteoarthritis (OA; N=405691), avascular necrosis (AVN; N=17060), fracture (N=104265), inflammatory arthritis (IA; N=5720) (includes rheumatoid arthritis [RA], spondylarthritis [SpA], including ankylosing spondylitis, and psoriatic arthritis [PsA]), vs. other. We identified underlying diagnoses using primary diagnosis codes and diabetes and complications using secondary diagnosis codes. We performed multivariable-adjusted regression analyses for clinical and healthcare utilization outcomes as endpoints, adjusted for race, age, sex, hospital bed size, census region, and teaching status.

Results: Total cohort population was 591,891, with 101,385 classified as diabetic. Mean age was 68.75, mean length of stay (LOS) was 2.73 days, and 58.20% were female. Overall, DM was associated with increased LOS, non-routine discharge (i.e., to a facility), and acute renal failure (ARF) (p≤0.05 each). Patients in the OA or fracture cohorts with DM were more likely to have non-routine discharges (p≤0.001 each). DM was significantly associated with an increased risk of longer LOS and ARF in OA, fracture, and IA cohorts (p≤0.03 each). DM was associated with increased risk of blood transfusions (p=0.031), and a lower risk of pneumonia and prosthetic complications in the fracture cohort (p≤0.016 each).

Conclusion: DM was associated with increased healthcare utilization and ARF following primary THA, indicating associated healthcare resource and clinical burden. The variation in association of DM with outcomes post-primary THA for people with AVN or fractures, identifies differential effect in elective versus non-elective cases that needs further study.

Supporting image 1

Supporting image 2


Disclosures: S. Chandrupatla: None; K. Rumalla: None; J. Singh: Other, 2, 6, 11, 11, 12, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix, Charlotte’s Web, 12, Atai life sciences, kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, 12, speaker’s bureau of Simply Speaking, other, 12, received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Elec, Other, 12, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam.

To cite this abstract in AMA style:

Chandrupatla S, Rumalla K, Singh J. Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/diabetes-mellitus-impacts-primary-total-hip-arthroplasty-outcomes-a-national-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diabetes-mellitus-impacts-primary-total-hip-arthroplasty-outcomes-a-national-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology